Skip to content

GenSight Biologics reports its cash position as of December 31, 2016

Paris, France, 27 January 2017 – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported its cash position as of December 31, 2016.

Please find the full PDF press released attached

GenSight Biologics
Thomas Gidoin
Chief Financial Officer
ir@gensight-biologics.com
+33 (0)1 76 21 72 20
NewCap
I
nvestor Relations
Florent Alba
gensight@newcap.eu
+33 (0)1 44 71 98 55
Rooney Partners
Media Relations
Marion Janic
mjanic@rooneyco.com
+1-212-223-4017

Source: Gensight